Thymosin Alpha-1 at the stocktaking table

Viral breakthrough and antibody changes

In a 2009 review of chronic hepatitis B trials, the comparison was between lamivudine alone and lamivudine with Thymosin Alpha-1 added. The combination had better virological responses and less viral breakthrough: the virus was less likely to regain ground during treatment. Control of the infection during treatment leaves questions about the patient's symptoms and longer-term health unanswered.

The background to a 2022 Cochrane review protocol describes eight trials involving 583 patients. HBeAg seroconversion, a change from a hepatitis B viral marker to its antibody, occurred in 45.1% with the combination and 15.2% with lamivudine alone. Those are blood-test outcomes. The summary does not establish whether patients felt better or lived longer.

Less viral breakthrough and a change in an antibody test describe different responses. Neither result alone tells us how a patient felt.

A long clinical history

Thymosin Alpha-1 is a 28-amino-acid peptide; its manufactured counterpart is called thymalfasin. A review covering four decades of clinical work reports approval in more than 35 countries, principally around chronic viral hepatitis and immune support. Thymalfasin has no FDA approval in the United States, and compounded thymosin alpha-1 medicines are not FDA-approved.

The length of that history impressed me. It also spans very different meanings of a response. In the cancer literature, the molecule is investigated alongside chemotherapy and immunotherapy for melanoma, liver cancer and lung cancer. Disease control and treatment toxicity matter here. A favourable immune marker leaves a further question: what happened to the cancer and to the person undergoing care?

The sepsis trial

An inventory also needs its disappointments. The 2025 TESTS sepsis trial enrolled 1,106 adults at 22 centres and found no statistically significant reduction in deaths at 28 days: 23.4% with thymosin alpha-1 and 24.1% with placebo. Earlier sepsis work had looked more encouraging. This result deserves an ordinary, prominent place on the shelf.

Here the outcome was survival over a defined period. The hepatitis blood-test results cannot answer that question. Each entry in this stocktake needs its own outcome and its own limits.

Browse the record

The clinical trials start with the liver work and follow the measured outcomes into cancer, sepsis and COVID-19. For the name itself, the definition and origins untangle thymalfasin, TA1 and the other thymosins.

Side effects and personal reports deserve their own space; an itchy injection site and a claim of fewer colds have very different evidential standing. The dosage record describes what trial participants received under medical supervision. It supplies no personal treatment plan.